Abstract
BackgroundAlthough methotrexate (MTX) is the recognized cornerstone of rheumatoid arthritis (RA) therapy, the bioavailability (BA) of oral MTX may be compromised in doses greater than 15 mg/week. In contrast, parenteral...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
